A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...